Global Alcoholic Hepatitis Therapeutic 麻豆原创 Research Report 2023

Publication ID:

PB502234749

Publication Date:

February 7, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Alcoholic hepatitis is a kind of liver disease usually affects people who are used to be heavy drinkers. It can cause short and long-term liver damage. Liver is a major organ of body functions to remove poisons such as alcohol from blood. It鈥檚 damaged by long time heavy drinking of alcohol. Usually occur in 30% of long- time alcohol drinkers. Asymptomatic steatohepatitis is also as alcoholic hepatitis the term is used to describe the acute onset of symptomatic hepatitis. Symptoms include changes I appetite, dry mouth, yellowing of skin or eyes, weight loss, fever and fatigue. Sometime alcoholic hepatitis could get serious conditions include fluid buildup in the abdomen, confusion or brain fog and bleeding in esophagus or stomach. Treatment for alcoholic hepatitis involves therapies and drinking cessation to ease the sign and symptoms of liver damage. Corticosteroids are the current main treatment for alcoholic hepatitis in patients who do not have contraindication for steroid treatment. Corticosteroids are the medications have shown short-term benefits in increasing survival of certain people suffer with alcoholic hepatitis. Pentoxifylline is recommend to patients who can鈥檛 take corticosteroids. Studies indicate that pentoxifylline might not be effective for people with mild alcoholic hepatitis or people who have not respond to steroid treatment.
Highlights
The global Alcoholic Hepatitis Therapeutic market was valued at US$ 2824.4 million in 2022 and is anticipated to reach US$ 3839.4 million by 2029, witnessing a CAGR of 5.3% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The global alcoholic hepatitis therapeutics market is expected to witness a favorable growth during the forecast period. Increasing incidence of liver diseases and high success rate of pipeline drugs are the major factors which increase global alcoholic hepatitis market. Moreover high adoption rate for novel therapeutic products and increasing prevalence of alcoholic liver disease are some other factors that are expected to fuel the demand of global alcoholic hepatitis market. Global alcoholic hepatitis market shows potential to be expanding and lucrative field due to increasing merger and acquisitions among pharmaceutical companies to develop advance therapies for treating liver diseases. Furthermore, increased focus on retaining best quality of life is one the factor contributing to the growth of the market. However increasing health care expenditure, stringent reimbursement policies and high development cost are some factors that might hinder the growth of alcoholic hepatitis therapeutics market in forecast period.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Alcoholic Hepatitis Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alcoholic Hepatitis Therapeutic.
The Alcoholic Hepatitis Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Alcoholic Hepatitis Therapeutic market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alcoholic Hepatitis Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Alkermes
Conatus pharmaceuticals
Dainippon sumitomo pharma
Generon corporation
Immuron limited
Lupin Laboratories
Intercept Pharmaceuticals
Teva Pharmaceuticals
Sanofi-Aventis
Segment by Type
Monoclonal Antibodies
Caspase Protease Inhibitor
Corticosteroids
Hemorheologic Agents
Anabolic Steroids
Hepatotropic Hormones
Sulfhydryl Agents
Others
Segment by Application
Hospitals and Clinics
Research and Development
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alcoholic Hepatitis Therapeutic companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Alcoholic Hepatitis Therapeutic 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies
1.2.3 Caspase Protease Inhibitor
1.2.4 Corticosteroids
1.2.5 Hemorheologic Agents
1.2.6 Anabolic Steroids
1.2.7 Hepatotropic Hormones
1.2.8 Sulfhydryl Agents
1.2.9 Others
1.3 麻豆原创 by Application
1.3.1 Global Alcoholic Hepatitis Therapeutic 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals and Clinics
1.3.3 Research and Development
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Alcoholic Hepatitis Therapeutic 麻豆原创 Perspective (2018-2029)
2.2 Alcoholic Hepatitis Therapeutic Growth Trends by Region
2.2.1 Global Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Alcoholic Hepatitis Therapeutic Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Alcoholic Hepatitis Therapeutic Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Alcoholic Hepatitis Therapeutic 麻豆原创 Dynamics
2.3.1 Alcoholic Hepatitis Therapeutic Industry Trends
2.3.2 Alcoholic Hepatitis Therapeutic 麻豆原创 Drivers
2.3.3 Alcoholic Hepatitis Therapeutic 麻豆原创 Challenges
2.3.4 Alcoholic Hepatitis Therapeutic 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alcoholic Hepatitis Therapeutic Players by Revenue
3.1.1 Global Top Alcoholic Hepatitis Therapeutic Players by Revenue (2018-2023)
3.1.2 Global Alcoholic Hepatitis Therapeutic Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Alcoholic Hepatitis Therapeutic 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Alcoholic Hepatitis Therapeutic Revenue
3.4 Global Alcoholic Hepatitis Therapeutic 麻豆原创 Concentration Ratio
3.4.1 Global Alcoholic Hepatitis Therapeutic 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alcoholic Hepatitis Therapeutic Revenue in 2022
3.5 Alcoholic Hepatitis Therapeutic Key Players Head office and Area Served
3.6 Key Players Alcoholic Hepatitis Therapeutic Product Solution and Service
3.7 Date of Enter into Alcoholic Hepatitis Therapeutic 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Alcoholic Hepatitis Therapeutic Breakdown Data by Type
4.1 Global Alcoholic Hepatitis Therapeutic Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Alcoholic Hepatitis Therapeutic Forecasted 麻豆原创 Size by Type (2024-2029)
5 Alcoholic Hepatitis Therapeutic Breakdown Data by Application
5.1 Global Alcoholic Hepatitis Therapeutic Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Alcoholic Hepatitis Therapeutic Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Alcoholic Hepatitis Therapeutic 麻豆原创 Size (2018-2029)
6.2 North America Alcoholic Hepatitis Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Country (2018-2023)
6.4 North America Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Alcoholic Hepatitis Therapeutic 麻豆原创 Size (2018-2029)
7.2 Europe Alcoholic Hepatitis Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Country (2018-2023)
7.4 Europe Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Alcoholic Hepatitis Therapeutic 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Alcoholic Hepatitis Therapeutic 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Alcoholic Hepatitis Therapeutic 麻豆原创 Size (2018-2029)
9.2 Latin America Alcoholic Hepatitis Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alcoholic Hepatitis Therapeutic 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Alcoholic Hepatitis Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Alcoholic Hepatitis Therapeutic 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alkermes
11.1.1 Alkermes Company Detail
11.1.2 Alkermes Business Overview
11.1.3 Alkermes Alcoholic Hepatitis Therapeutic Introduction
11.1.4 Alkermes Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.1.5 Alkermes Recent Development
11.2 Conatus pharmaceuticals
11.2.1 Conatus pharmaceuticals Company Detail
11.2.2 Conatus pharmaceuticals Business Overview
11.2.3 Conatus pharmaceuticals Alcoholic Hepatitis Therapeutic Introduction
11.2.4 Conatus pharmaceuticals Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.2.5 Conatus pharmaceuticals Recent Development
11.3 Dainippon sumitomo pharma
11.3.1 Dainippon sumitomo pharma Company Detail
11.3.2 Dainippon sumitomo pharma Business Overview
11.3.3 Dainippon sumitomo pharma Alcoholic Hepatitis Therapeutic Introduction
11.3.4 Dainippon sumitomo pharma Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.3.5 Dainippon sumitomo pharma Recent Development
11.4 Generon corporation
11.4.1 Generon corporation Company Detail
11.4.2 Generon corporation Business Overview
11.4.3 Generon corporation Alcoholic Hepatitis Therapeutic Introduction
11.4.4 Generon corporation Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.4.5 Generon corporation Recent Development
11.5 Immuron limited
11.5.1 Immuron limited Company Detail
11.5.2 Immuron limited Business Overview
11.5.3 Immuron limited Alcoholic Hepatitis Therapeutic Introduction
11.5.4 Immuron limited Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.5.5 Immuron limited Recent Development
11.6 Lupin Laboratories
11.6.1 Lupin Laboratories Company Detail
11.6.2 Lupin Laboratories Business Overview
11.6.3 Lupin Laboratories Alcoholic Hepatitis Therapeutic Introduction
11.6.4 Lupin Laboratories Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.6.5 Lupin Laboratories Recent Development
11.7 Intercept Pharmaceuticals
11.7.1 Intercept Pharmaceuticals Company Detail
11.7.2 Intercept Pharmaceuticals Business Overview
11.7.3 Intercept Pharmaceuticals Alcoholic Hepatitis Therapeutic Introduction
11.7.4 Intercept Pharmaceuticals Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.7.5 Intercept Pharmaceuticals Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Detail
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Alcoholic Hepatitis Therapeutic Introduction
11.8.4 Teva Pharmaceuticals Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.8.5 Teva Pharmaceuticals Recent Development
11.9 Sanofi-Aventis
11.9.1 Sanofi-Aventis Company Detail
11.9.2 Sanofi-Aventis Business Overview
11.9.3 Sanofi-Aventis Alcoholic Hepatitis Therapeutic Introduction
11.9.4 Sanofi-Aventis Revenue in Alcoholic Hepatitis Therapeutic Business (2018-2023)
11.9.5 Sanofi-Aventis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Alkermes
Conatus pharmaceuticals
Dainippon sumitomo pharma
Generon corporation
Immuron limited
Lupin Laboratories
Intercept Pharmaceuticals
Teva Pharmaceuticals
Sanofi-Aventis

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.